NCT05241379 (AURA-2) is a NA clinical trial of Amber UI System in Overactive Bladder, sponsored by Amber Therapeutics Ltd.

Who is sponsoring NCT05241379?

NCT05241379 is sponsored by Amber Therapeutics Ltd.

What drugs are being tested in NCT05241379?

Interventions in NCT05241379: Amber UI System.

What condition does NCT05241379 study?

NCT05241379 studies Overactive Bladder, Urge Incontinence.

Is NCT05241379 still recruiting?

NCT05241379 is currently completed. Last updated 12 August 2024.

Last reviewed 2024-08-12 · How we verify

NCT05241379: AURA-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AURA-2: Augmenting Urinary Reflex Activity

Completed NA Last updated 12 August 2024

What this trial tests

NA trial testing Amber UI System in Overactive Bladder in 13 participants. Completed in 15 April 2024.

Timeline

30 November 2022

Primary endpoint
15 April 2024

15 April 2024

Quick facts

Lead sponsor	Amber Therapeutics Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	30 November 2022
Primary completion	15 April 2024
Estimated completion	15 April 2024
Sites	1 location across Belgium

Drugs / interventions tested

Amber UI System

Conditions studied

Overactive Bladder — all drugs for Overactive Bladder →
Urge Incontinence — all drugs for Urge Incontinence →

Sponsor

Amber Therapeutics Ltd — full company profile →

Who can join

Adults 18 to 75, female only, with Overactive Bladder or Urge Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AMBER AURA-2 study (Augmenting Urinary Reflex Activity 2) is a short-duration (6 month) safety and electrophysiological study using an implanted Amber UI system and two electrode leads to provide closed-loop pudendal nerve stimulation for the treatment of urinary incontinence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05241379 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amber Therapeutics Ltd
Last refreshed: 12 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05241379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing